methyl 6-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-3-phenyl-1-benzothiophene-2-carboxylate | 925454-12-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: methyl 6-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-3-phenyl-1-benzothiophene-2-carboxylate
• 英文别名: methyl 3-phenyl-6-((4-(1,1,1-trifluoro-2-hydroxybutan-2-yl)-1H-1,2,3-triazol-1-yl)methyl)benzo[b]thiophene-2-carboxylate；methyl 3-phenyl-6-[[4-(1,1,1-trifluoro-2-hydroxybutan-2-yl)triazol-1-yl]methyl]-1-benzothiophene-2-carboxylate
• CAS: 925454-12-2
• 化学式: C₂₃H₂₀F₃N₃O₃S
• 分子量: 475.491
• InChiKey: DYXRPCJFAUISEU-UHFFFAOYSA-N

物化性质

• 沸点：
  663.7±65.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  methyl 6-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-3-phenyl-1-benzothiophene-2-carboxylate 在 二异丁基氢化铝 作用下， 以 四氢呋喃 为溶剂， 生成 1,1,1-trifluoro-2-(1-([2-(hydroxymethyl)-3-phenyl-1-benzothien-6-yl]methyl)-1H-1,2,3-triazol-4-yl)butan-2-ol
  参考文献：
  名称：

  Potent and selective 5-LO inhibitor bearing benzothiophene pharmacophore: Discovery of MK-5286

  摘要：

  The strategy and SAR studies that led to the discovery of a novel potent and orally available 5-lipoxygenase (5-LO) inhibitor 3-(4-fluorophenyl)-6-({4-[(1S)-1-hydroxy-1-(trifluoromethyl) propyl]-1H-1,2,3-triazol-1-yl} methyl)-1-benzothiophene-2-carboxamide ((S)-21 or MK-5286) were described. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.024
• 作为产物：
  描述：

  methyl 3-chloro-6-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-1-benzothiophene-2-carboxylate 、 苯硼酸 在 palladium diacetate 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 methyl 6-({4-[1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-3-phenyl-1-benzothiophene-2-carboxylate
  参考文献：
  名称：

  Potent and selective 5-LO inhibitor bearing benzothiophene pharmacophore: Discovery of MK-5286

  摘要：

  The strategy and SAR studies that led to the discovery of a novel potent and orally available 5-lipoxygenase (5-LO) inhibitor 3-(4-fluorophenyl)-6-({4-[(1S)-1-hydroxy-1-(trifluoromethyl) propyl]-1H-1,2,3-triazol-1-yl} methyl)-1-benzothiophene-2-carboxamide ((S)-21 or MK-5286) were described. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.024

文献信息

• WO2007/16784
  申请人：——

  公开号：——

  公开（公告）日：——
• NOVEL SUBSTITUTED 1,2,3-T II AZOLYLMETHYL-BENZOTHIOPHENE OR -INDOLE AND THEIR USE AS LEUKOTIIENE BIOSYNTHESIS INHIBITORS
  申请人：Merck Frosst Canada Ltd.

  公开号：EP1915369A1

  公开（公告）日：2008-04-30
• [EN] NOVEL SUBSTITUTED 1,2,3-T?AZOLYLMETHYL-BENZOTHIOPHENE OR -INDOLE AND THEIR USE AS LEUKOT?ENE BIOSYNTHESIS INHIBITORS<br/>[FR] NOUVEAU 1,2,3-T?AZOLYLMÉTHYLE-BENZOTHIOPHÈNE SUBSTITUÉS OU -INDOLE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BIOSYNTHÈSE LEUKOT?ÈNE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2007016784A1

  公开（公告）日：2007-02-15

  [EN] The instant invention provides compounds of Formula I which are leukotpene biosynthesis inhibitors. Z is a fused (optionally sulfo-oxidized) thiophen ring or a fused pyrrol ring R2-R4 are selected from a variety of substituents Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti¬ inflammatory and cytoprotective agents.
  [FR] La présente invention se rapporte à des composés de formule I qui sont des inhibiteurs de biosynthèse de leukotpene. Z est un cycle fusionné (optionnellement sulfo-oxydisé) ou un noyau pyrolle fusionné, R2-R4 sont choisis parmi divers substituants. Les composés de la formule I sont utiles en tant qu'agents anti-athéroscléreux, anti-asthmatiques, anti-allergiques, anti-inflammatoires et cytoprotecteurs.
• Potent and selective 5-LO inhibitor bearing benzothiophene pharmacophore: Discovery of MK-5286
  作者：Lianhai Li、Carl Berthelette、Anne Chateauneuf、Marc Ouellet、Claudio F. Sturino、Zhaoyin Wang

  DOI：10.1016/j.bmcl.2010.10.024

  日期：2010.12

  The strategy and SAR studies that led to the discovery of a novel potent and orally available 5-lipoxygenase (5-LO) inhibitor 3-(4-fluorophenyl)-6-(4-[(1S)-1-hydroxy-1-(trifluoromethyl) propyl]-1H-1,2,3-triazol-1-yl} methyl)-1-benzothiophene-2-carboxamide ((S)-21 or MK-5286) were described. (C) 2010 Elsevier Ltd. All rights reserved.